NICE
NHS England and NICE announce plans for new Cancer Drugs Fund
November 19, 2015Medical Communications, Research and Development Cancer Drugs Fund, NHS England, NICE
A 12-week consultation on draft proposals for a revamped Cancer Drugs Fund (CDF) has been launched by NHS England and NICE, …
NICE decision restricts Bayer’s Xofigo to select prostate cancer patients
November 19, 2015Research and Development, Sales and Marketing Bayer, NICE, prostate cancer
NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
NICE rejects Roche’s Kadcyla for NHS; price still too high
November 17, 2015Manufacturing and Production, Sales and Marketing Cancer Drugs Fund, Kadcyla, NHS England, NICE, Roche
NICE has published final draft guidance on Roche’s Kadcyla as a breast cancer treatment, deciding that the drug’s price remains …
Otsuka kidney drug earns first NICE nod
October 28, 2015Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan
NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
NICE recommends four treatments for arthritis in children
October 22, 2015Medical Communications, Research and Development NICE, arthritis, jia
UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …
NICE recommends four treatments for arthritis in children
October 22, 2015Medical Communications, Research and Development NICE, arthritis, jia
UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …
NICE issues draft guidance for MSD’s Ezetrol
October 21, 2015Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol
NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol. The guidance updates …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
NICE requests more evidence on Duchenne muscular dystrophy therapy
October 16, 2015Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren
NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …
ABPI hits back at Prime Minister’s criticism of high drug prices
October 15, 2015Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease
The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …
NICE launches new service to speed NHS adoption of health technologies
October 13, 2015Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, OMA, market access, office for market access
NICE is introducing a new service, the Office for Market Access (OMA), to work with industry to speed up NHS …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
Latest content
FibroFind appoints Lee Borthwick as CEO
